Skip to main content

Share story

Science

NASA and partners conduct Crew-12 Flight Readiness Review

Crew-12 official portrait Image: Primary
NASA, SpaceX, and international partners are holding a Flight Readiness Review to evaluate preparations for the Crew-12 mission. The meeting is intended to determine whether conditions support a launch. The review is taking place at NASA Kennedy Space Center. Participants are examining the readiness of the SpaceX crew transportation system, the International Space Station, and the support provided by partner agencies. The process is designed to conclude with a certification of flight readiness. The Crew-12 mission is planned to transport a crew of four to the space station. The astronauts include Jessica Meir and Jack Hathaway from NASA along with Sophie Adenot of the European Space Agency. Andrey Fedyaev of Roscosmos completes the team for the eight-month science mission. The results of the review are scheduled for release later today. Announcements will be made through the mission blog and associated social media accounts. Interested parties may follow updates via @NASAKennedy on X or the NASA Kennedy account on Facebook.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from NASA and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.